Our vision is health transparency

Jim Kean is a senior technology executive with an innovative career focused on making healthcare easier by pioneering disruptive consumer-oriented health, wellness, and fitness digital experiences. The consistent theme: creating user delight, loyalty, and retention while fundamentally re-engineering the cost of delivery.

Prior to joining Molecular You, Jim was initially General Manager of the Consumer Platform for Cambia Health; a Blue Cross Blue Shield insurer based out of Portland, OR. In this capacity he drove development of a next generation platform for omni-channel consumer engagement. Later he became General Manager of Value Management which focused on population health analytics.

Jim is Founder and former CEO of WellnessFx™ a venture backed San Francisco based company that made it easy and affordable for consumers to manage key areas of their healthcare lives by providing inexpensive, profile driven access to targeted health content, diagnostic and tele-health services, and HIPAA secure storage. January of 2013, the company was named 2012 Innovative Company of the Year by the Nutritional Business Journal. In December 2013 the company merged with Thorne Healthtech (THRN).

In 1995, Jim founded Sapient Health Network (SHN) which became the Consumer facing business of WebMD. As President of SHN, Jim pioneered the concept of online consumer health communities, building some of the largest and most loyal groups on the Web today. The company’s service was named one of the “Seven Best Websites of 1998” by Business Week. In 1999, SHN merged with WebMD and later Healtheon to form the current version of WebMD. SHN represented the consumer facing side of the merged companies. Today over 23 million consumers per month visit WebMD for health advice. After WebMD, Jim served as Entrepreneur in Residence with Alloy Ventures of Palo Alto.

‍

Rob was the founding CEO and is the current President and CSO of Molecular You Corporation. Molecular You was spun out of the Personalized Medicine Initiative (PMI) which Rob co-founded with leading scientists and clinicians in Canada to develop the framework and technologies to bring personalized medicine into healthcare practice.  As the Chief Operating Officer of the PMI, Rob supported the establishment of six new companies, of which Rob was co-founder of three of them, including Molecular You.. He helped raise funding for all of them and has been at the forefront of developing the framework and technologies to bring personalized medicine into healthcare practice. Backed by his expertise in molecular diagnostics, molecularly targeted drug discovery and development, biochemistry and regulatory compliance, Rob has also been involved in leading drug discovery and development projects at Sanofi, Xenon, Neuromed and CDRD. Rob received extensive training in the molecular mechanisms of endocrinology while completing his Ph.D. at the University of Alberta and Harvard Medical School and Post-Doctoral Fellowships at Hospital for Sick Children, Toronto and IGBMC, Strasbourg, France. In addition to Rob’s scientific accomplishments, he has been involved in the raising of more than $37M in funding. Rob is also co-founder of GenXys Health Care Systems, Personalized Biomarkers Incorporated, Mesentech Corporation and Novobind.

‍

Gene has spent his career operating at the forefront of emergent technologies. He brings over 20 years of experience translating creative ideas into innovative products and business innovations — developing breakthrough products in Internet of Things (IoT), healthcare, and wearable technology sectors.

His superpower is fostering collaborative, high performing cultures by empowering teams and individuals to share ideas, experiment, and iterate. As a result, he has built and led multiple successful technology teams in both startup and complex corporate environments.

While at J&J, he built and led a large global engineering team tasked with launching transformational Internet of Things (IoT) platforms that spanned cloud, mobile, big data, analytics, sensors, and devices. This service delivered multiple new product lines and new business models across different sectors

Prior to that, Gene co-founded and led a startup specializing in sensor technologies for mobile, wearable, and IoT devices, which pioneered the use of MEMS sensors for activity tracking and gesture recognition. Gene holds multiple technology patents and numerous awards in mobile innovation.

‍

David holds a Ph.D. from Yale (1991) and is a Professor in the Departments of Biological Sciences and Computing Science at the University of Alberta. He is also a senior research officer and the director of the Nano Life Science program at the Canadian National Research Council’s National Institute for Nanotechnology. From 2006-2009, David led the “Human Metabolome Project” (HMP), a multi-university, multi-investigator project that cataloged all of the known metabolites in human tissues and bio-fluids. Using advanced methods David and his colleagues identified or found evidence for more than 8500 endogenous metabolites. The methods and ideas developed for the HMP have helped lay the foundation for a number of clinical metabolomics projects currently being pursued in his lab. David has published more than 40 papers in the field of metabolomics and currently directs the Metabolomics Innovation Centre.

‍

Dr. Khaleghi has helped launch a series of successful health technology companies, with a focus on diagnostics. With degrees in medicine, bioengineering, computer science, and business, Dr. Khaleghi has served as Founding Chief Medical Officer, Co-Founder, or Board Member of approximately a dozen early stage health technology companies, with several exits.

‍

Christoph is recognized as a pioneer and leading figure in the development of mass spec based methods for protein quantification using Multiple Reaction Monitoring (MRM). He is also the Director of the UVic–Genome BC Proteomics Centre and has published more than 180 peer-reviewed papers in scientific journals. His research is centered around the improvement, development and application of proteomics technologies with a major focus on techniques for quantitative targeted proteomics for clinical diagnostics. Christoph received his B.S., M.Sc. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke-UNC Proteomics Facility and held a faculty position at UNC Medical School in Chapel Hill, NC (2001-2006). Christoph is also involved in promoting proteomics research and education through his involvement with HUPO (International Council Member), the British Columbia Proteomics Network (co-leader) and the Canadian National Proteomics Network (VP External, Chair of the Board of Directors).

‍

Dr. Haiyan Yang is an accomplished executive with a strong drive for innovation and growth in the health technology industry. With over 20 years of experience in research development and management, Haiyan has extensive expertise in molecular diagnostics, laboratory operations, and regulatory compliance. She holds a Ph.D. in Biology from the University of Victoria, complemented by a postdoctoral research position at the National Cancer Institute and an MBA degree from Simon Fraser University.

Haiyan's impressive scientific and management background led her to thrive as an R&D scientist at Inimex and Migenix, and in a leadership role at the University of British Columbia's Facility for Infectious Disease and Epidemic Research, a prominent containment level 3 facility in Canada. As a co-founder and Vice President of Operations at Molecular You, her ultimate goal is to deliver personalized, AI-driven health solutions that transform lives across the US, Canada, and the world.

‍

Ash Anwar is an accomplished professional with a diverse background spanning molecular biology, biochemistry, data science, and business. After completing his undergraduate degree in molecular biology and biochemistry from SFU, he pursued a graduate degree in experimental medicine from UBC, complemented by a research fellowship in Ophthalmology at Harvard Medical School. Fueled by an entrepreneurial spirit, Ash has co-founded several startups in the health and data industry, while also authoring business books on managing distributed virtual/hybrid teams and learning venture capital.

Equipped with an MBA from UBC's Sauder School of Business, Ash currently serves as the Senior Director of Data at Molecular You. In this role, he contributes to the company's data vision and strategy, while also overseeing data management and data science functions.

Ash has also authored key publications and patents for Molecular You, establishing himself as a thought leader in the industry. With over a decade of experience in health and data science, Ash is committed to pushing the boundaries of these fields and leveraging emerging technologies to revolutionize healthcare. Ash's goal is to improve patient outcomes by harnessing the power of data-driven insights and transforming them into actionable strategies. With a strong foundation in science, business, and entrepreneurship, Ash is dedicated to making a meaningful impact in the intersection of health, data, and AI.

‍